Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatmentUpdated data from phase III CLL14 study of Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) showed more than 60% of previously untreated people with chronic lymphocytic leukaemia remained in remission five years after starting treatment[1]Final analysis of phase III GALLIUM study showed meaningful improvement in progression-free survival was main...
Source: Roche Investor Update - June 10, 2022 Category: Pharmaceuticals Source Type: news
Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatmentUpdated data from phase III CLL14 study of Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) showed more than 60% of previously untreated people with chronic lymphocytic leukaemia remained in remission five years after starting treatment[1]Final analysis of phase III GALLIUM study showed meaningful improvement in progression-free survival was main...
Source: Roche Media News - June 10, 2022 Category: Pharmaceuticals Source Type: news
Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS
(MedPage Today) -- Eprenetapopt combined with azacitidine as maintenance therapy after hematopoietic cell transplantation (HCT) improved outcomes for patients with TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 25, 2022 Category: Hematology Source Type: news
Blast Counts Not Enough to Distinguish MDS From AML, Experts Say Blast Counts Not Enough to Distinguish MDS From AML, Experts Say
Oncologists argue that in differentiating myelodysplastic syndrome from acute myeloid leukemia, more than just bone marrow blast cutoff should be considered.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Aggressive Supportive Treatment for COVID-19 in Leukemia and MDS Aggressive Supportive Treatment for COVID-19 in Leukemia and MDS
New findings provide preliminary evidence to use aggressive supportive treatment of COVID-19 in patients with acute leukemias and myelodysplastic syndromes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Myeloid Patients Respond Robustly to Moderna COVID Vaccine Myeloid Patients Respond Robustly to Moderna COVID Vaccine
Robust responses to COVID vaccination were seen in patients with acute myeloid leukemia and myelodysplastic syndrome.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Zydus Cadila gets USFDA nod to market generic cancer drug in US
The company has received final approval from the US Food and Drug Administration (USFDA) to Decitabine for Injection in the strength of 50 mg/vial single-dose vial, Zydus Cadila said in a statement. Decitabine is used to treat myelodysplastic syndromes, certain types of blood or bone marrow cancer. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 20, 2021 Category: Pharmaceuticals Source Type: news
Dr Reddy's launches cancer drug in Canada
"Our launch of Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada's Multiple Myeloma and Myelodysplastic Syndrome (MDS) patient population," Vinod Ramachandran, Vice President and General Manager, Dr. Reddy's Laboratories Canada said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 2, 2021 Category: Pharmaceuticals Source Type: news
FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and deb...
Source: Roche Media News - July 21, 2021 Category: Pharmaceuticals Source Type: news
FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and deb...
Source: Roche Investor Update - July 21, 2021 Category: Pharmaceuticals Source Type: news
MDS Highlights From ASCO 2021 MDS Highlights From ASCO 2021
Dr Amy DeZern, of Johns Hopkins University School of Medicine, reviews key studies on myelodysplastic syndromes presented at ASCO 2021, including phase 2 data on enasidenib in higher-risk MDS patients.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 30, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
LEXINGTON, Mass., April 19, 2021 -- (Healthcare Sales & Marketing Network) -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to announce that the U.S. Food ... Biopharmaceuticals, Oncology, FDA Curis, acute myeloid leukemia, myelodysplastic syndromes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 19, 2021 Category: Pharmaceuticals Source Type: news
Image analysis based on machine learning reliably identifies haematological malignancies
(University of Helsinki) Image analysis utilising neural networks can help identify details in tissue samples which are difficult to discern by the human eye. A study conducted at the University of Helsinki demonstrated that the technique makes it possible to accurately determine genetic mutations in the cancer cells of patients suffering from myelodysplastic syndrome, a malignant blood disorder. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 22, 2021 Category: Cancer & Oncology Source Type: news
Whole-Genome Sequencing Is Accurate for Myeloid Cancers
WEDNESDAY, March 10, 2021 -- A streamlined whole-genome sequencing approach can provide rapid and accurate genomic profiling for acute myeloid leukemia (AML) or myelodysplastic syndromes, according to a study published in the March 11 issue of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 10, 2021 Category: Pharmaceuticals Source Type: news
Leukemia: New Adverse Event With PARP Inhibitors in Cancer Leukemia: New Adverse Event With PARP Inhibitors in Cancer
Late toxicities in the form of myelodysplastic syndrome and acute myeloid leukemia can occur even a brief exposure to PARP inhibitors, and both are associated with a high mortality rate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 8, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
